RLMD · Relmada Therapeutics, Inc. · Debt
$4.21
+0.05 (+1.20%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$449.19M
Shares
106.69M
Volume · Nov 13
1.74M
Avg daily vol (3M)
1.35M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Debt Profile
Completed filing coverage through Mar 19, 2026Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Read debt and covenant terms in your AI or your code through MCP and the API →Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Notes payable, including current maturities | 2020-12-31 | USD 0 | 10-K filed 2021-03-24 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Key facts
CIK
1553643
CUSIP
75955J402
13F (30d)
91 filings
78 filers
Visit website
Investor relations